SEC Form 4 · accession 0001708138-17-000002
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Stahl
Officer — EVP Research and Development
Period of report
Jun 1, 2017
Accepted (ET)
Jun 5, 2017 · 4:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2017 | M | 4,527 | $268.40 | A | 28,477 | D | |
| Common Stock | Jun 1, 2017 | F | 2,612 | $464.98 | D | 25,865 | D | |
| Common Stock | Jun 1, 2017 | F | 1,068 | $464.98 | D | 24,797 | D | |
| Common Stock | Jun 1, 2017 | M | 6,017 | $145.70 | A | 30,814 | D | |
| Common Stock | Jun 1, 2017 | F | 1,885 | $464.98 | D | 28,929 | D | |
| Common Stock | Jun 1, 2017 | F | 2,167 | $464.98 | D | 26,762 | D | |
| Common Stock | Jun 2, 2017 | S | 100 | $466.33 | D | 26,662 | D | |
| Common Stock | Jun 2, 2017 | S | 100 | $469.83 | D | 26,562 | D | |
| Common Stock | Jun 2, 2017 | S | 100 | $470.49 | D | 26,462 | D | |
| Common Stock | Jun 2, 2017 | S | 100 | $472.10 | D | 26,362 | D | |
| Common Stock | Jun 2, 2017 | S | 100 | $474.82 | D | 26,262 | D | |
| Common Stock | Jun 2, 2017 | S | 100 | $475.33 | D | 26,162 | D | |
| Common Stock | Jun 2, 2017 | S | 100 | $476.52 | D | 26,062 | D | |
| Common Stock | Jun 2, 2017 | S | 100 | $479.00 | D | 25,962 | D | |
| Common StockF2 | Jun 2, 2017 | S | 309 | $480.71 | D | 25,653 | D | |
| Common StockF3 | Jun 2, 2017 | S | 695 | $481.64 | D | 24,958 | D | |
| Common StockF4 | Jun 2, 2017 | S | 808 | $482.56 | D | 24,150 | D | |
| Common StockF5 | Jun 2, 2017 | S | 200 | $483.42 | D | 23,950 | D | |
| Common Stock | holding | — | — | — | 10,000 | I | by GRAT | |
| Common Stock | holding | — | — | — | 5,000 | I | by GRAT | |
| Common Stock | holding | — | — | — | 5,647 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $145.70 | Jun 1, 2017 | M | 6,017 | D | Feb 28, 2013 | Dec 17, 2017 | Common Stock | 6,017 | 0 | D |
| Non-Qualified Stock Option (right to buy) | $268.40 | Jun 1, 2017 | M | 4,527 | D | Nov 10, 2013 | Dec 17, 2017 | Common Stock | 4,527 | 0 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2Represents volume-weighted average price of sales of 309 shares of Company stock on June 2, 2017 at prices ranging from $480.30 to $480.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price.
- F3Represents volume-weighted average price of sales of 695 shares of Company stock on June 2, 2017 at prices ranging from $481.25 to $481.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price.
- F4Represents volume-weighted average price of sales of 808 shares of Company stock on June 2, 2017 at prices ranging from $482.00 to $482.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price.
- F5Represents volume-weighted average price of sales of 200 shares of Company stock on June 2, 2017 at prices ranging from $483.11 to $483.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 2, 2017 at each separate price.